Physician profile
Mark A Studeny
NPI 1326008517
$6,754.57
in general payments reported to CMS, 2019-2025
29 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,138 · 2020: $678 · 2021: $822 · 2022: $248 · 2023: $609 · 2024: $737 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,868.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,768.09 | 2019-2024 | Amplatzer Talisman |
| Boston Scientific Corporation | $887.72 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $694.21 | 2019-2025 | Lifevest |
| Medtronic Vascular, INC. | $616.54 | 2019 | |
| Edwards Lifesciences Corporation | $562.56 | 2019-2024 | Sapien 3 Ultra Resilia |
| Abiomed | $410.58 | 2021-2024 | Impella |
| Astrazeneca Pharmaceuticals Lp | $251.24 | 2019-2024 | Farxiga, Wainua |
| Shockwave Medical, INC | $218.16 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $203.57 | 2019-2024 | |
| Amgen INC. | $162.87 | 2019-2021 | |
| Inspire Medical Systems, INC. | $137.91 | 2025 | Inspire |
| Zoll Circulation INC | $135.00 | 2024 | Downstream Cartridge, Therox Ds2 Console, Catheter |
| Lantheus Medical Imaging, INC. | $106.54 | 2023 | Definity |
| Cvrx, INC. | $84.96 | 2023 | Barostim Neo System |
| Celonova Biosciences, INC. | $83.52 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $70.62 | 2019-2020 | |
| Pfizer INC. | $64.33 | 2021-2024 | |
| Angiodynamics, INC. | $59.38 | 2019 | |
| Novo Nordisk INC | $38.17 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $34.92 | 2019-2021 | |
| Terumo Medical Corporation | $33.76 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.74 | 2019-2025 | Jardiance |
| Philips North America LLC | $20.02 | 2021 | |
| Cardiva Medical, INC. | $17.15 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Ge Healthcare | $15.39 | 2025 | |
| Medtronic, INC. | $13.64 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.86 | 2021 | |
| Gilead Sciences, INC. | $12.09 | 2019 | |
| Penumbra, INC. | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Studeny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.